文献速递甲状腺疾病

倾向主动监测而非手术的低危单灶甲状腺微小乳头状癌患者射频消融的前瞻性临床试验

A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery.
PubMed 文献 · Thyroid · 2024-01-01

这项前瞻性临床试验在2018至2021年单中心纳入100例倾向主动监测而非手术的低危单灶甲状腺微小乳头状癌成人患者,评估超声引导下射频消融的疗效与安全性。中位随访30个月,技术成功率达100%,98例中累计疾病进展率为3.1%(3/98),未观察到主要并发症,心理与社会生活质量评分显著改善。

要点

  • 低危单灶甲状腺微小乳头状癌倾向主动监测者,射频消融技术成功率达100%。
  • 98例随访至少1年者累计疾病进展率3.1%(3/98),未观察到主要并发症。
  • 心理(7.3 vs 8.0,p=0.002)与社会(8.0 vs 8.7,p=0.005)生活质量评分显著改善。

核心结论

  • 射频消融可为适合主动监测的非老年低危甲状腺微小乳头状癌患者有效且安全地控制肿瘤并改善生活质量,作者认为可作为一种合理策略。

研究设计与样本

  • 前瞻性临床试验,2018至2021年在单家三级转诊医院开展。
  • 227例年龄≤60岁、倾向主动监测而非立即手术的低危单灶甲状腺微小乳头状癌成人患者中,100例接受射频消融治疗。
  • 主要终点为疾病进展率,次要终点为技术成功、体积缩小率、并发症率与生活质量。

主要发现

  • 研究人群中位年龄42岁(范围27-59岁),女性占83%(83/100,CI 66.1-100)。
  • 中位随访30个月(范围12-56个月),100例均完成射频消融且技术成功。
  • 95.9%(94/98,CI 77.5-100.0)的消融区在末次随访时完全消失,中位体积缩小率在1年随访时为100.0%并持续至末次随访。
  • 至少随访1年的98例中累计疾病进展率为3.1%(3/98,CI 0.6-9.0):1例淋巴结转移接受手术,2例新发甲状腺微小乳头状癌(1例接受射频消融,1例继续主动监测)。
  • 未观察到主要并发症;心理生活质量评分基线7.3 vs 末次随访8.0(p=0.002)、社会评分8.0 vs 8.7(p=0.005)显著改善,躯体评分8.6 vs 8.5(p=0.99)无显著变化。

临床怎么用

  • 作者认为,对于适合主动监测的非老年低危甲状腺微小乳头状癌患者,射频消融可作为有效且安全控制肿瘤并改善生活质量的合理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Active surveillance (AS) of papillary thyroid microcarcinomas (PTMC) is emerging as an alternative to immediate surgery. While thermal ablation has also shown promise for low-risk PTMC, it has not been prospectively studied in patients appropriate for AS. This study aimed to evaluate the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for tumor control and quality of life (QoL) management in patients with PTMC who favored AS over immediate surgery. Methods: This prospective clinical trial was conducted at a single tertiary referral hospital from 2018 to 2021. Of 227 adult patients aged ≤60 years with low-risk unifocal PTMC favoring AS over immediate surgery, 100 patients underwent RFA for their management. The primary endpoint was the disease progression rate, and secondary endpoints were technical success, volume reduction rate (VRR), complication rates, and QoL. Results: The median age of the study population was 42 years (range, 27-59 years), and 83% (83/100, [CI: 66.1-100]) were female. The median follow-up was 30 months (range, 12-56 months). All 100 patients underwent RFA with technical success. Most of the ablation zones showed continuous volume reduction, and 95.9% (94/98, [CI: 77.5-100.0]) showed complete disappearance at the last follow-up. The median VRR was 100.0% at 1-year follow-up and persisted throughout the last follow-up. The cumulative disease progression rate among 98 patients who underwent at least 1-year follow-up was 3.1% (3/98, [CI: 0.6-9.0]); one patient had lymph node metastasis (treated with surgery), and two patients had new PTMC (1 treated with RFA, 1 ongoing AS). Major complications were not observed. Psychological (baseline vs. last follow-up, 7.3 vs. 8.0, p = 0.002) and social (8.0 vs. 8.7, p = 0.005) QoL scores significantly improved during follow-up without compromising physical QoL (8.6 vs. 8.5, p = 0.99). Conclusions: RFA can be a reasonable strategy for effectively and safely controlling tumors and improving QoL in non-elderly patients with low-risk PTMC appropriate for AS. Clinical Trial registration: This trial is registered with ClinicalTrials.gov: NCT03432299.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee JY, Na DG, Sim JS, et al. A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery. Thyroid. 2024. PMID: 39212950. doi:10.1089/thy.2024.0098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。